AI Article Synopsis
- The study investigates the relationship between liver enzyme levels and the severity of COVID-19, finding a significant link between elevated enzymes and worse outcomes.
- It analyzes data from 24 studies involving over 4,200 patients and uses statistical methods to ensure the findings are reliable and valid.
- Elevated liver enzymes, particularly ALT, AST, and LDH, are more common in severe cases of COVID-19, especially in males, suggesting these could serve as important markers for identifying at-risk patients.
Article Abstract
Aim: The current study aimed to report a pooled analysis of the association of the circulating levels of liver enzymes and total bilirubin with severe and non-severe COVID-19.
Background: The ongoing coronavirus outbreak is an important threat to health worldwide. Epidemiological data representing greater risk of liver failure in patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
Methods: Electronic databases were comprehensively searched using Medline, ISI Web of Science, EMBASE, and the Cochrane Library up to July 2020. Outcomes from each relevant study were pooled using a random-effects model. Heterogeneity was analyzed by Q test and I statistics. Sensitivity analysis was also evaluated.
Results: A total of 24 studies were included (4,246 patients) in this study. We found a significant association of COVID-19 severity with increased levels of ALT [SMD: 1.40 U/L; 95% CI (0.93, 1.88); < 0.05, I = 96.5%, 0.000 ], AST [SMD: 2.11 U/L; 95% CI (1.40, 2.83); < 0.05, I = 97.9%, 0.000], LDH [SMD: 3.88 U/L; 95% CI (2.70, 5); < 0.05, I = 98.7%, 0.000] and TBil [SMD: 1.08 mol/L; 95% CI (0.44, 1.72); = 0.001, I = 97.7, 0.000], whereas, ALP values [SMD: 0.31; 95% CI (-1.57, 2.20); = 0.74] was not significant between severe and non-severe COVID-19 patients. Moreover, elevated liver enzymes were found more in males [OR: 1.52, (95% CI 1.26, 1.83), < 0.05] with severe COVID-19 infection than in females.
Conclusion: The alterations of liver function indexes caused by SARS-CoV-2 infection suggested a potential prognosis biomarker for screening of severe patients at early stages of the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682972 | PMC |
Publication Analysis
Top Keywords
Similar Publications
The Effectiveness of Curcumin, Resveratrol, and Silymarin on MASLD: A Systematic Review and Meta-Analysis.
Food Sci Nutr
December 2024
Polyphenols, known for their potent antioxidant and anti-inflammatory properties, have emerged as promising, natural, and safe complementary treatment options for metabolic-associated steatotic liver disease (MASLD). Among these, curcumin, resveratrol, and silymarin are the most extensively studied; however, their differential effects on MASLD outcomes remain inconclusive. This systematic review and meta-analysis of RCTs aimed to evaluate the efficacy of curcumin, resveratrol, and silymarin in patients with MASLD.
View Article and Find Full Text PDF[Analysis of genetic association between exon polymorphisms of and and risky drinking behavior of alcoholic liver disease].
Zhonghua Yu Fang Yi Xue Za Zhi
December 2024
Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnosis,Shenzhen518035,China Department of Laboratory Medicine, The Second People's Hospital of Shenzhen,Shenzhen518035,China.
To analyze the correlation of exon rs1126671 and exon rs971074 polymorphisms with risky drinking behaviors and alcoholic liver disease. The patients with alcoholic liver disease diagnosed in the Gastroenterology Department of the People's Hospital of Hechi from November 2021 to June 2022, including 52 cases of alcoholic liver disease with positive risky drinking behaviors, 103 cases of non-alcoholic liver disease with positive risky drinking behaviors of the same gender and age, and 105 healthy subjects with no risky drinking behaviors as control groups were retrospectively analyzed. The serum total protein and albumin are detected by immunoturbidimetry and globulin is calculated by the difference method; the serum total bilirubin and direct bilirubin are detected by the nitrite oxidation method and indirect bilirubin is calculated by the difference method; alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase and γ-glutamyl transferase are detected by the substrate method.
View Article and Find Full Text PDFThe effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease.
J Diabetes Complications
December 2024
Department of Third Clinical College, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Background: Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) were often coexistent conditions driven by insulin resistance and systemic inflammation. Effective management strategies that address both metabolic disorders were urgently needed. This study investigates the effect of combining semaglutide, a glucagon-like peptide-1 receptor agonist, with metformin on liver inflammation and pancreatic beta-cell function in patients with T2DM and NAFLD.
View Article and Find Full Text PDFProstaglandin E1 administration post liver transplantation and renal outcomes: A retrospective single center experience.
World J Transplant
December 2024
Department of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI 48109, United States.
Background: Prostaglandin E1 (PGE1), or alprostadil, is a potent vasodilator that improves hepatic blood flow and reduces ischemia-reperfusion injury post-liver transplantation (LT). However, the benefits of PGE1 on renal function after LT have not yet been well described.
Aim: To assess the impact of PGE1 administration on renal function in patients who underwent liver or liver-kidney transplant.
Severe Outcomes of Pneumocystis Pneumonia: A 10-year Retrospective Cohort Study.
Transpl Infect Dis
December 2024
Transplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, Canada.
Background: A considerable knowledge gap exists in predicting severe Pneumocystis pneumonia (PCP) outcomes following PCP diagnosis.
Methods: In this retrospective cohort, we studied immunocompromised patients with PCP admitted to 5 University Health Network centers in Canada (2011-2022). The study outcome included severe PCP, a composite of 21-day ICU admission or 28-day all-cause mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!